Ingevity (NGVT) has caught investor attention after a recent share price move, with the stock last closing at US$74.32. That price anchors how the market currently values its materials and specialty chemicals operations.
Recent trading has been choppy for Ingevity, with a 1-day share price move that dipped 1.39%, a 7-day share price return of 4.63%, and a 30-day share price gain of 2.64%. This points to momentum that has cooled slightly from the stronger 23.68% year to date share price return and longer term total shareholder returns of 38.04% over 1 year and 85.52% over 3 years, even as the 5-year total shareholder return remains slightly negative.
Scan how Ingevity compares with other materials and specialty chemicals plays by reviewing the hand picked 33 high quality undervalued stocks that currently combine quality fundamentals with compressed valuations.
Ingevity now trades at a clear discount to both analyst targets and one intrinsic value estimate. The recent rally narrows the gap, but how far below fair value does the current US$74.32 price still sit?
Most Popular Narrative: 16% Undervalued
At a last close of $74.32, the most followed narrative on Ingevity anchors fair value at $89. That gap reflects a story built around portfolio reshaping, margin repair, and cash generation rather than just short term share price moves.
Accelerated portfolio repositioning and the advanced-stage divestiture of non-core, lower-margin businesses (Industrial Specialties and CTO refinery) are expected to drive a step-change in margin profile, enabling greater focus and capital allocation toward higher-growth, value-added specialty chemicals supporting both revenue quality and sustained EBITDA margin improvement.
See why 1 investors see Ingevity as 16% undervalued.
Result: Fair Value of $89 (UNDERVALUED)
Still, weakness in Advanced Polymer Technologies and ongoing tariff pressure could strain margins, especially if planned divestitures or portfolio shifts do not deliver the expected benefits.
Find out about the key risks to this Ingevity narrative.
Another View On Ingevity’s Valuation
The earlier narrative leans on analyst targets and long term earnings scenarios. A different lens uses today’s P/E ratios. On that score, Ingevity trades at 101.4x earnings versus a fair ratio estimate of 30.1x, the US Chemicals sector at 23.1x, and peer companies at 26.5x. That is a wide gap. Is the market overpaying for the current story or underestimating future earnings power?
To see how this earnings multiple gap could close in either direction and what it might mean for future returns, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed messages across price moves and valuation can pull you in different directions, so review Ingevity's data yourself and decide where you land. To see the full balance of potential upsides and the issues investors are worried about, start with these 3 key rewards and 3 important warning signs
Looking for more investment ideas beyond Ingevity?
If you stop with Ingevity, you risk missing other opportunities that fit your style, so put a few minutes into broadening your watchlist with targeted screeners.
- Spot resilient performers with strong finances by reviewing the list of solid balance sheet and fundamentals (24 results) that highlight businesses pairing balance sheet strength with solid fundamentals.
- Hunt for quality at compressed prices by scanning the 33 high quality undervalued stocks that surface financially sound companies trading below their implied worth.
- Secure potential income ideas by checking the 5 dividend fortresses that focus on higher yielding payouts backed by more durable profiles.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com